Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Macular Edema Therapeutics - Pipeline Assessment and Market Forecasts to 2018The Macular Edema Therapeutics Market is forecast to Show Significant Growth until 2018
By: Rajesh Gunnam grow at a Compound Annual Growth Rate (CAGR) of 8.9%, and reach $2,567m by 2018. This growth is primarily attributed to the increase in the prevalence and incidence rates of diabetes across the seven major markets such as the US, the UK, Japan, Germany, Spain, Italy and France. Macular edema is a slowly progressing disease, and diabetes is cited as the main cause of macular edema. The growth in the market will be supported and driven by the increased use of off-label drugs such as Avastin (bevacizumab) GlobalData has found that the current competition in the macular edema therapeutics market is intense, due to the increased use of off-label products by the physicians. This is due to lack of approved drugs in the market, which forces physicians to use off-label drugs to treat patients. Currently, there are only two approved products available in the market – Lucentis (ranibizumab) GlobalData found that there are 30 products in different stages of development. The late stage pipeline of macular edema seems very promising. There are approximately 13 first-in-class molecules in different stages of development. Iluvien is currently in the NDA filing stage, while VEGF Trap-Eye, Lucentis and Ozurdex are currently in Phase III for the treatment of DME. As there is no approved drug for the treatment of Diabetic Macular Edema (DME), these products are expected to fulfill the unmet needs and will provide physicians with a better choice in treating diabetic as well as non-diabetic macular edema. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ GlobalData found that the available treatment options are moderately successful in meeting the market demand. There is a high unmet need in the macular edema market. The high unmet need shows that the market is underserved by the currently available products. There are only two approved products in the market for macular edema following RVO – Ozurdex and Lucentis. Since companies investing in such diseases face a higher risk of being denied an approval, not many products have entered the market over the last decade. This explains the lack of safe and efficacious drugs in the market. Newer molecules in the late stage pipeline are few in number but novel drug delivery systems to deliver drugs at a constant rate to the Back-of-the- GlobalData, the industry analysis specialist, has released its new report, “Macular Edema Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Macular Edema Therapeutics market. The report identifies the key trends shaping and driving the global Macular Edema Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Macular Edema Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number